I am reminded of an old saying"Nobody gets fired for buying IBM"...

I am reminded of an old saying
"Nobody gets fired for buying IBM" in the 70s and 80s because IBM was so dominant in the mainframe industry.
my point is:
I have read over many years discussions about various biotech stocks, how BPs would be falling over themselves offering deals due to the market size, the wonder of the drugs, etc.
But..... it does take 2 to tango, and from the BP side, there are people making decisions in big acquisitions, and these decision makers would want to be as confident as possible pushing for a big acquisition of non revenue producing co.
lest the decision backs fire and put a big dent or worse, a stop to their careers.
Having said that, IMU sure looks like making steady progress towards building a stronger and stronger case for somebody in BPs to make that pitch to their BOD.
So far, practising oncologists and researchers and fda seem to be in agreement about IMU's offerings.

or I could be talking through the wrong end again.
DYOR.